Aripiprazole CAS 129722-12-9 Mimọ>99.0% (HPLC) API
Olupese Ipese Intermediates ti Aripiprazole Pẹlu Giga Mimo
Aripiprazole API CAS 129722-12-9
1- (2,3-Dichlorophenyl) piperazine Hydrochloride CAS 119532-26-2
7-Hydroxy-3,4-Dihydro-2(1H)-Quinolinone CAS 22246-18-0
7- (4-Bromobutoxy) -3,4-Dihydro-2 (1H) - Quinolinone CAS 129722-34-5
| Orukọ Kemikali | Aripiprazole |
| Awọn itumọ ọrọ sisọ | 7-[4-[4- (2,3-Dichlorophenyl)-1-Piperazinyl] butoxy] -3,4-Dihydro-2 (1H) -Quinolinone |
| Nọmba CAS | 129722-12-9 |
| NỌMBA CAT | RF-PI2270 |
| Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu |
| Fọọmu Molecular | C23H27Cl2N3O2 |
| Òṣuwọn Molikula | 448.39 |
| Solubility | Ailokun Soluble ninu Omi;Insoluble ni kẹmika |
| Brand | Ruifu Kemikali |
| Nkan | Awọn pato |
| Ifarahan | Funfun tabi Fere White Crystalline Powder |
| Idanimọ | Nipasẹ IR;Nipasẹ HPLC |
| Solubility | Soluble ni Acetic Acid, Tiotuka diẹ ninu Ethanol |
| Ojuami Iyo | 136.0 ~ 140.0 ℃ |
| Pipadanu lori Gbigbe | <0.50% |
| Aloku lori Iginisonu | <0.10% |
| Awọn irin Heavy | ≤20ppm |
| Awọn ohun elo ti o ku | |
| Ethanol | ≤1000ppm |
| DMF | ≤200ppm |
| Awọn nkan ti o jọmọ | |
| Eyikeyi Nikan Aimọ | <0.20% |
| Lapapọ Awọn Aimọ | <1.00% |
| Mimọ / Analysis Ọna | > 99.0% (HPLC) |
| Ayẹwo | 98.0% ~ 102.0% (lori ipilẹ Anhydrous) |
| Awọn idiwọn Micro | |
| Lapapọ Aerobic makirobia kika | ≤1000 cfu/g |
| Iwukara ati Mold Ni idapo | ≤100 cfu/g |
| E·Coli | Àìsí |
| Patogeniki Iṣeto | Àìsí |
| Igbeyewo Standard | Standard Enterprise |
| Lilo | API;Antipsychotic |
Package: Igo, 5kg / Aluminiomu tin, 25kg / Paali ilu, tabi gẹgẹbi ibeere alabara
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin
Aripiprazole (CAS: 129722-12-9) jẹ iru tuntun ti awọn itọsẹ quinoline ti o ni ọra gaan, awọn iṣe iṣe elegbogi rẹ ni pe kii ṣe antagonist olugba postsynaptic dopamine D2 nikan, ṣugbọn tun presynaptic dopamine D2 agonist olugba, o tun le ṣojulọyin D1, D3, D4 awọn olugba.Aripiprazole jẹ iran keji aiṣedeede antipsychotic ati egboogi-depressant pẹlu iṣẹ agonist apakan ni dopamine D2 ati awọn olugba serotonin 5-HT1A ati iṣẹ antagonist ni awọn olugba serotonin 5-HT2A.Awọn iye Ki jẹ 0.34 nM, 0.8 nM, 1.7 nM, ati 3.4 nM, ni atele, fun dopamine D2 ati D3, serotonin 5-HT1A ati 5-HT2A awọn olugba.A lo Aripiprazole fun itọju schizophrenia ati awọn rudurudu ti o ni ibatan.Bristol-Myers Squibb ati Otsuka Pharmaceutical Company kede pe European Union ti fọwọsi Abilify (Aripiprazole) ni itọju ohun elo atokọ schizophrenia.Schizophrenia ni ipa lori 1% ti olugbe agbaye, ati diẹ sii ni awọn ọdọ.Schizophrenia ni ipa lori ero, iṣakoso ẹdun ati agbara ṣiṣe ipinnu ti alaisan.Awọn alaisan ti o ni schizophrenia yoo ni awọn aami aiṣan bii hallucinations ati awọn ẹtan, awọn alaisan ti o ni awọn ami aisan odi jẹ yiyọkuro awujọ, aini awọn iyipada ẹdun.Ni ọdun 2002 FDA fọwọsi Abilify fun itọju schizophrenia, eyiti o ni awọn agbara iwọn lilo marun: 5 mg, 10 mg, 15 mg, 20 mg ati 30 mg, niwon ifọwọsi rẹ.
